Cowen, Per­cep­tive lead $79.5M Se­ries B for 's­tand­out' biotech shep­herd­ing on­colyt­ic virus to clin­ic

As sev­er­al Big Phar­ma play­ers se­cure biotech part­ners in the on­colyt­ic virus space for new im­muno-on­col­o­gy com­bos, Cowen and Per­cep­tive Ad­vi­sors have come out with their own bet on a start­up that promis­es to shine.

The mar­quee in­vestors are join­ing MPM, Deer­field, Cel­gene, Astel­las, Arkin Bio Ven­tures and UBS On­col­o­gy Im­pact Fund in back­ing the drug de­vel­op­er, On­corus, which will now de­ploy the $79.5 mil­lion in Se­ries B cash to­ward clin­i­cal de­vel­op­ment of its lead pro­gram. Oth­er new in­vestors in­clude Sur­vey­or Cap­i­tal, Sphera Funds, IMM In­vest­ment, QUAD In­vest­ment Man­age­ment, UTC In­vest­ment, SV In­vest­ment Corp and Shin­han In­vest­ment-Pri­vate Eq­ui­ty, the last five of which are Ko­re­an-based funds.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER